Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens
July 23, 2019 01:51 ET
|
Curetis
- Final LRT BAL panel demonstrates overall weighted average sensitivity of up to 94.7% and overall weighted average specificity of up to 98.4% - Unyvero provides results after approximately five...
Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing
July 04, 2019 02:02 ET
|
Curetis
Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing Patent broadly covers genetic biomarkers and biomarker combinations indicating antibiotic...
Curetis To Attend Key Conferences in the Third Quarter of 2019
July 02, 2019 02:00 ET
|
Curetis
Amsterdam, the Netherlands, and Holzgerlingen, Germany, July 2, 2019, 08:00 am CET - Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular...
Curetis Reports Results of the Annual General Meeting Held on June 27, 2019
June 28, 2019 01:59 ET
|
Curetis
- All proposed AGM resolutions approved by shareholders Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, June 28, 2019, 08:00 am CEST / 02:00 am EDT - Curetis N.V. (the...
New Data on Curetis’ Unyvero LRT Panel for Pneumonia to be Presented at ASM Microbe 2019
June 04, 2019 02:11 ET
|
Curetis
- Several scientific conference contributions outline benefits of U.S. FDA-cleared Unyvero LRT Application Cartridge in both endotracheal aspirate and bronchoalveolar lavage samples - Study shows...
Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples
May 23, 2019 02:00 ET
|
Curetis
- Test shows overall weighted average sensitivity of 90.1% (94.7%) and overall weighted average specificity of 98.4% (97.9%) in prospective (retrospective) sample cohort - U.S. FDA 510(k)...
Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville
May 21, 2019 00:55 ET
|
Curetis
- Curetis and EIB agree on equity-linked participation upon maturity of new EUR 5 million tranche of debt financing - Yorkville to provide funding of EUR 1.5 million to Curetis Amsterdam, the...
Curetis Announces Financial Results for the First Three Months of 2019
May 17, 2019 01:00 ET
|
Curetis
Curetis Announces Financial Results for the First Three Months of 2019 - Total year-on-year revenue growth of approximately 45% - Successful implementation of corporate re-organization and...
Curetis to Hold Annual General Shareholders’ Meeting on June 27, 2019
May 15, 2019 08:00 ET
|
Curetis
Curetis to Hold Annual General Shareholders’ Meeting on June 27, 2019 Amsterdam, the Netherlands, Holzgerlingen, Germany and San Diego, CA, USA, May 15, 2019, 02:00 pm CEST / 08:00 am EDT - Curetis...
Press release: Curetis’ Subsidiary Ares Genetics Introduces NGS Services for Pharma and Public Health Sector at Upcoming ECCMID 2019
April 12, 2019 02:00 ET
|
Curetis
Strain-typing and AMR detection of clinical isolates based on ARESdbSet-up of own NGS service laboratory in Vienna, Austria Vienna, Austria, Holzgerlingen, Germany, and Amsterdam, The...